Small molecules that sensitize HIV-1 infected cells to antibody dependent cellular cytotoxicity

A method of treating HIV-1 in a human infected with HIV-1 or preventing HIV-1 infection in a human susceptible to infection with HIV-1 comprising administering to the human a therapeutically effective amount of a compound of formula (I):

• wherein:
• n is 1;
• X is —CH2—;
• Y is —N(C(O)OC1-6alk)-, —N(SO2R9)—, —N(C(O)R8)—, —N(C(O)NR9R10)—, or —N(C(═NH)NR9R10)—;
• Z is C(O)NH—;
• R1 is H;
• R2 is H;
• (i) R3 is H, halogen, C1-6alkyl, —OC1-6alkyl, or C1-6haloalkyl;
• and R4 is halogen;
• or (ii) R3 is halo or C1-6haloalkyl;
• and R4 is H;
• R5 is H, halogen, C1-6alkyl, —OC1-6alkyl, or C1-6haloalkyl;
• R6 and R7 are each H or NH2;
• R8 is —OC1-6alkyl, —O—C1-6alk-NH2, —NH(C1-6alkyl), —N(C1-6alkyl)(C1-6alkyl), —NH—C1-6alk-NH2, phenyl, or heteroaryl;
• and
• R9 and R10 are, independently, H, C1-6alkyl, —C(O)OC1-6alkyl, halogenated C1-6alkyl, C3-8cycloalkyl, aryl, or heteroaryl;
• wherein R8, R9, and R10 are, independently, optionally substituted by halo, CN, OC1-6alkyl, —NHC(O)(C1-6alkyl), or unsubstituted C1-6alkyl;
• or a pharmaceutically acceptable salt thereof.